Merck KGaA Yönetim

Yönetim kriter kontrolleri 3/4

Şu anda CEO hakkında yeterli bilgiye sahip değiliz.

Anahtar bilgiler

Belen Garijo Lopez

İcra Kurulu Başkanı

€10.5m

Toplam tazminat

CEO maaş yüzdesi	14.2%
CEO görev süresi	9.8yrs
CEO sahipliği	n/a
Yönetim ortalama görev süresi	6.1yrs
Yönetim Kurulu ortalama görev süresi	5.6yrs

Son yönetim güncellemeleri

Recent updates

CEO Tazminat Analizi

Belen Garijo Lopez'un ücretlendirmesi Merck KGaA'un kazancına kıyasla nasıl değişti?
Tarih	Toplam Tazminat	Maaş	Şirket Kazançları
Sep 30 2024	n/a	n/a	€3b
Jun 30 2024	n/a	n/a	€3b
Mar 31 2024	n/a	n/a	€3b
Dec 31 2023	€11m	€2m	€3b
Sep 30 2023	n/a	n/a	€3b
Jun 30 2023	n/a	n/a	€3b
Mar 31 2023	n/a	n/a	€3b
Dec 31 2022	€11m	€2m	€3b
Sep 30 2022	n/a	n/a	€3b
Jun 30 2022	n/a	n/a	€3b
Mar 31 2022	n/a	n/a	€3b
Dec 31 2021	€9m	€1m	€3b
Sep 30 2021	n/a	n/a	€3b
Jun 30 2021	n/a	n/a	€3b
Mar 31 2021	n/a	n/a	€2b
Dec 31 2020	€7m	€1m	€2b
Sep 30 2020	n/a	n/a	€2b
Jun 30 2020	n/a	n/a	€1b
Mar 31 2020	n/a	n/a	€2b
Dec 31 2019	€6m	€1m	€1b
Sep 30 2019	n/a	n/a	€1b
Jun 30 2019	n/a	n/a	€1b
Mar 31 2019	n/a	n/a	€938m
Dec 31 2018	€7m	€1m	€1b
Sep 30 2018	n/a	n/a	€2b
Jun 30 2018	n/a	n/a	€2b
Mar 31 2018	n/a	n/a	€2b
Dec 31 2017	€6m	€1m	€3b

Tazminat ve Piyasa: Belen 'nin toplam tazminatı ($USD 11.15M ), German pazarındaki benzer büyüklükteki şirketler için ortalamanın üzerindedir ($USD 4.83M ).

Tazminat ve Kazançlar: Belen 'in tazminatı, şirketin son bir yıldaki performansıyla tutarlıydı.

CEO

Belen Garijo Lopez (64 yo)

9.8yrs

Görev süresi

€10,527,000

Tazminat

Ms. Belen Garijo Lopez, M.D., is Chair of Executive Board and Chief Executive Officer of MERCK Kommanditgesellschaft auf Aktien since May 01, 2021. She served as Vice Chairman of the Executive Board and De...

Liderlik Ekibi

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Belen Garijo Lopez	Chair of Executive Board & CEO	9.8yrs	€10.53m	Veri yok
Helene von Roeder	CFO & Member of Executive Board	1.3yrs	€1.23m	Veri yok
Kai Beckmann	CEO of Electronics & Member of the Executive Board	13.6yrs	€8.26m	Veri yok
Peter Guenter	CEO of Healthcare Business & Member of Executive Board	3.8yrs	€5.58m	Veri yok
Matthias Heinzel	CEO of Life Science Sector & Member of Executive Board	3.6yrs	€5.22m	Veri yok
Barbara Weiland	Chief Compliance Officer	5.3yrs	Veri yok	Veri yok
Dietmar Eidens	Head of the Global HR Business Partner Organization	9.8yrs	Veri yok	Veri yok
Frank Gotthardt	Head of Corporate & Government Relations - Europe	15.4yrs	Veri yok	Veri yok
Marc Horn	Head of Life Science Controlling	no data	Veri yok	Veri yok
Michael Heckmeier	Head of the Display Materials Business Unit for Performance Materials	7.6yrs	Veri yok	Veri yok
Hans-Joachim Neumann	Head of Integrated Supply Chain	6.1yrs	Veri yok	Veri yok
Tina Sandmann	Head of Internal Auditing	5.3yrs	Veri yok	Veri yok

6.1yrs

Ortalama Görev Süresi

57yo

Ortalama Yaş

Deneyimli Yönetim: MRK 'un yönetim ekibi deneyimli ve deneyimlidir ( 6.1 yıldır).

Yönetim Kurulu Üyeleri

İsim	Pozisyon	Görev süresi	Tazminat	Sahiplik
Dietmar Oeter	Independent Member of Supervisory Board	10.5yrs	€50.80k	Veri yok
Alexander Putz	Member of Supervisory Board	4.5yrs	€50.80k	Veri yok
Stefan Palzer	Supervisory Board Member	less than a year	Veri yok	Veri yok
Barbara Lambert	Independent Member of Supervisory Board	1.3yrs	€30.50k	Veri yok
Sascha Held	Vice Chair of Supervisory Board	5.6yrs	€89.30k	Veri yok
Michael Kleinemeier	Independent Chairman of Supervisory Board	5.6yrs	€50.80k	Veri yok
Anne Lange	Independent Member of Supervisory Board	5.6yrs	€50.80k	Veri yok
Christian Raabe	Independent Member of Supervisory Board	5.6yrs	€65.80k	Veri yok
Daniel Thelen	Independent Member of Supervisory Board	5.6yrs	€65.80k	Veri yok
Simon Thelen	Independent Member of Supervisory Board	5.6yrs	€50.80k	Veri yok
Birgit Biermann	Member of Supervisory Board	2.3yrs	€50.80k	Veri yok
Katja Vila	Supervisory Board Member	less than a year	Veri yok	Veri yok

5.6yrs

Ortalama Görev Süresi

55yo

Ortalama Yaş

Deneyimli Yönetim Kurulu: MRK 'nin yönetim kurulu üyeleri deneyimli olarak kabul edilir (ortalama görev süresi 5.6 yıldır).

Merck KGaA Yönetim

Yönetim kriter kontrolleri 3/4

Anahtar bilgiler

Son yönetim güncellemeleri

Merck KGaA, Annual General Meeting, Apr 25, 2025

Merck KGaA, Annual General Meeting, Apr 26, 2024

Merck Announces CFO Changes

Merck KGaA, Darmstadt, Germany, Announces Management Changes for North America and Global Innovative Medicine Franchises in Healthcare

Recent updates

Merck KGaA to Report Q4, 2024 Results on Mar 06, 2025

Third quarter 2024 earnings: EPS and revenues miss analyst expectations

Merck KGaA Announces Phase III Maneuver Trial of Pimicotinib

Merck KGaA (XTRA:MRK) completed the acquisition of Unity Semiconductor SAS for €160 million.

Merck KGaA Announces First Patient Dosed in Phase III Study of Oral Cladribine in Generalized Myasthenia Gravis (gMG)

Second quarter 2024 earnings: EPS in line with analyst expectations despite revenue beat

Merck KGaA (XTRA:MRK) intends to acquire Unity Semiconductor SAS.

Merck KGaA (XTRA:MRK) intends to acquire Unity Semiconductor SAS.

Merck KGaA Provides Update on Phase III TrilynX Study in Locally Advanced Head and Neck Cancer

Merck KGaA Provides Updates on the Oncology Pipeline and Focused Approach to the Research and Development of Potential New Medicines Designed to Improve the Futures of Cancer Treatment

First quarter 2024 earnings: EPS exceeds analyst expectations

Merck KGaA, Annual General Meeting, Apr 25, 2025

Upcoming dividend of €2.20 per share

Daiichi Sankyo and Merck Announce That the First Patient Has Been Dosed in the Rejoice-Ovarian01 Phase 2/3 Trial Evaluating the Efficacy and Safety of Investigational Raludotatug Deruxtecan (R-DXd) in Patients with Platinum-Resistant Ovarian Cancer

Dividend of €2.20 announced

Full year 2023 earnings: Revenues and EPS in line with analyst expectations

Merck Kgaa, Darmstadt, Germany Provides Update on Phase III Results for Evobrutinib in Relapsing Multiple Sclerosis

Merck Launches First Ever AI Solution to Integrate Drug Discovery and Synthesis

Third quarter 2023 earnings: EPS exceeds analyst expectations while revenues lag behind

Merck KGaA to Report Q4, 2023 Results on Mar 07, 2024

Merck Receives Positive EU CHMP Opinion for PREVYMIS for Prevention of CMV Disease in High-Risk Adult Kidney Transplant Recipients and Extended 200-Day Dosing in Adult HSCT Recipients at Risk for Late CMV Infection and Disease

Second quarter 2023 earnings: Revenues exceed analyst expectations

Merck KGaA, Annual General Meeting, Apr 26, 2024

First quarter 2023 earnings: Revenues in line with analyst expectations

Merck Announces CFO Changes

Upcoming dividend of €2.20 per share at 1.3% yield

Full year 2022 earnings: Revenues in line with analyst expectations

Now 21% undervalued

Now 20% undervalued

Now 21% undervalued

Now 21% undervalued

Third quarter 2022 earnings: Revenues exceed analyst expectations

Merck Reportedly to Put Pigments Unit Up for Sale Again

MERCK Kommanditgesellschaft auf Aktien to Report Q4, 2022 Results on Mar 02, 2023

MERCK Kommanditgesellschaft auf Aktien Provides Earnings Guidance for the Full Year 2022

Gerresheimer and Merck Transform Primary Packaging into Digital Twins

Second quarter 2022 earnings: Revenues exceed analyst expectations

First quarter 2022 earnings: Revenues and EPS in line with analyst expectations

Upcoming dividend of €1.85 per share

Full year 2021 earnings: Revenues in line with analyst expectations

MERCK Kommanditgesellschaft auf Aktien to Report Nine Months, 2022 Results on Nov 10, 2022

Third quarter 2021 earnings released

Price target increased to €195

Second quarter 2021 earnings released: EPS €1.71 (vs €0.67 in 2Q 2020)

Price target increased to €170

Head of Oncology Development Klaus Edvardsen has left the company

Head of Oncology Development Klaus Edvardsen has left the company

Head of Oncology Development Klaus Edvardsen has left the company

Head of Oncology Development Klaus Edvardsen has left the company

Head of Oncology Development Klaus Edvardsen has left the company

Head of Oncology Development Klaus Edvardsen has left the company

Head of Oncology Development Klaus Edvardsen has left the company

Head of Oncology Development Klaus Edvardsen has left the company

Head of Oncology Development Klaus Edvardsen has left the company

Head of Oncology Development Klaus Edvardsen has left the company

Head of Oncology Development Klaus Edvardsen has left the company

Head of Oncology Development Klaus Edvardsen has left the company

Head of Oncology Development Klaus Edvardsen has left the company

Head of Oncology Development Klaus Edvardsen has left the company

Head of Oncology Development Klaus Edvardsen has left the company

Head of Oncology Development Klaus Edvardsen has left the company

Merck Launches New, High-Purity Synthetic Cholesterol Product

First quarter 2021 earnings released

Merck KGaA Provides Earnings Guidance for the First Quarter and Full Year of 2021

Chairman of Executive Board & CEO Stefan Oschmann has left the company

Upcoming dividend of €1.40 per share

Merck KGaA Reports Topline Data for Bintrafusp Alfa as Second-Line Monotherapy Treatment in Biliary Tract Cancer

Genome and Company Signs Second Clinical Trial Collaboration and Supply Agreement (Phase 2) with Merck Kgaa, Darmstadt, Germany and Pfizer for Immuno-Oncology Microbiome Study

Full year 2020 earnings released: EPS €4.57 (vs €2.97 in FY 2019)

Revenue beats expectations, earnings disappoint

New 90-day low: €133